ECSP10010447A - Inhibidores de cinasa pim y métodos para su uso - Google Patents

Inhibidores de cinasa pim y métodos para su uso

Info

Publication number
ECSP10010447A
ECSP10010447A EC2010010447A ECSP10010447A ECSP10010447A EC SP10010447 A ECSP10010447 A EC SP10010447A EC 2010010447 A EC2010010447 A EC 2010010447A EC SP10010447 A ECSP10010447 A EC SP10010447A EC SP10010447 A ECSP10010447 A EC SP10010447A
Authority
EC
Ecuador
Prior art keywords
pim kinase
new compounds
methods
kinase inhibitors
pharmaceutically
Prior art date
Application number
EC2010010447A
Other languages
English (en)
Inventor
Jiong Lan
Matthew Burger
Mika K Lindvall
Gisele Nishiguchi
Michelle Tetalman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41055566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010447(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP10010447A publication Critical patent/ECSP10010447A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de las fórmulas I y II, a sus tautómeros, estereoisómeros y polimorfos, y a las sales farmacéuticamente aceptables, ésteres, metabolitos o pro-fármacos de los mismos, a composiciones de los nuevos compuestos junto con vehículos farmacéuticamente aceptables, y al uso de los nuevos compuestos, ya sea solos o bien en combinación con cuando menos un agente terapéutico adicional, en la inhibición de la actividad de la cinasa Pim y/o en la profilaxis o el tratamiento de cáncer.
EC2010010447A 2008-03-03 2010-09-03 Inhibidores de cinasa pim y métodos para su uso ECSP10010447A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3335908P 2008-03-03 2008-03-03

Publications (1)

Publication Number Publication Date
ECSP10010447A true ECSP10010447A (es) 2010-10-30

Family

ID=41055566

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010447A ECSP10010447A (es) 2008-03-03 2010-09-03 Inhibidores de cinasa pim y métodos para su uso

Country Status (21)

Country Link
EP (2) EP2262802B1 (es)
JP (1) JP5412448B2 (es)
KR (1) KR20100120709A (es)
CN (2) CN104098559A (es)
AR (1) AR070531A1 (es)
AU (1) AU2009221134B2 (es)
BR (1) BRPI0909102A2 (es)
CA (1) CA2717388A1 (es)
CL (1) CL2009000483A1 (es)
CO (1) CO6290687A2 (es)
EA (1) EA201001412A1 (es)
EC (1) ECSP10010447A (es)
ES (2) ES2443496T3 (es)
IL (1) IL207865A0 (es)
MA (1) MA32135B1 (es)
MX (1) MX2010009739A (es)
PE (1) PE20091577A1 (es)
TW (1) TW200942536A (es)
UY (1) UY31679A1 (es)
WO (1) WO2009109576A1 (es)
ZA (1) ZA201006128B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
HUE029236T2 (en) 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
WO2010026124A1 (en) * 2008-09-02 2010-03-11 Novartis Ag Picolinamide derivatives as kinase inhibitors
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
MY156727A (en) 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
ES2557316T3 (es) * 2009-09-08 2016-01-25 F. Hoffmann-La Roche Ag Compuestos de piridín-3-il-carboxamida 4-sustituidos y métodos de utilización
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EA201290957A1 (ru) 2010-04-07 2013-04-30 Ф.Хоффманн-Ля Рош Аг Пиразол-4-илгетероциклилкарбоксамидные соединения и способы их применения
CN103391936B (zh) * 2010-04-30 2016-04-27 国立大学法人东京大学 抗癌剂
AR084691A1 (es) 2010-05-21 2013-06-05 Incyte Corp Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
JP2013530199A (ja) * 2010-07-06 2013-07-25 ノバルティス アーゲー キナーゼ阻害剤として有用な環状エーテル化合物
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
JP2014506915A (ja) * 2011-03-04 2014-03-20 ノバルティス アーゲー キナーゼ阻害剤としての四置換シクロヘキシル化合物
UY33930A (es) * 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
US9187486B2 (en) 2011-04-29 2015-11-17 Amgen Inc. Bicyclic pyridazine compounds as Pim inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
EP2734205B1 (en) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
CN102924444B (zh) * 2011-08-11 2015-07-08 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CA2845191A1 (en) 2011-09-27 2013-04-04 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
PE20150194A1 (es) * 2012-05-21 2015-02-08 Novartis Ag Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
WO2014033630A1 (en) * 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
WO2014033631A1 (en) * 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
WO2014048939A1 (en) 2012-09-26 2014-04-03 F. Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ME03780B (me) * 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
MX384910B (es) 2013-03-06 2025-03-14 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak.
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
TW201605866A (zh) * 2013-08-23 2016-02-16 英塞特公司 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN111386261B (zh) * 2017-09-20 2024-03-22 利德发现中心有限责任公司 香豆素衍生物、其制备方法及其在癌症治疗中的用途
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7393348B2 (ja) 2018-01-30 2023-12-06 インサイト・コーポレイション （１－（３－フルオロ－２（トリフルオロメチル）イソニコチニル）ピぺリジン―４－オン）を作製するためのプロセス及び中間体
CN113768934A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
CA3095580A1 (en) 2018-04-13 2019-10-17 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
AU2020221247B2 (en) 2019-02-12 2024-12-12 Sumitomo Pharma America, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN110452164B (zh) * 2019-09-10 2022-07-22 上海皓鸿生物医药科技有限公司 Pim447关键中间体的制备方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
JP2026509318A (ja) 2022-10-31 2026-03-18 スミトモ・ファーマ・アメリカ・インコーポレイテッド 骨髄増殖性新生物を治療するためのｐｉｍ１阻害剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
PE20050444A1 (es) * 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
JP2008543965A (ja) * 2005-06-28 2008-12-04 タケダ・ケンブリッジ・リミテッド 複素環式非ペプチドｇｎｒｈ拮抗薬
CA2628455A1 (en) * 2005-11-10 2007-05-24 Merck Sharp & Dohme Corp. Imidazopyrazines as protein kinase inhibitors
WO2007123269A1 (ja) * 2006-04-19 2007-11-01 Astellas Pharma Inc. アゾールカルボキサミド誘導体
AR063531A1 (es) * 2006-10-31 2009-01-28 Schering Corp Derivados de anilinopiperazina y composicion farmaceutica
MX2009004786A (es) * 2006-10-31 2009-06-05 Schering Corp Derivados de anilinopiperazina y sus metodos de uso.
JP5103604B2 (ja) * 2006-10-31 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としての２−アミノチアゾール−４−カルボン酸アミド
ES2431163T3 (es) * 2007-03-01 2013-11-25 Novartis Ag Inhibidores de PIM quinasa y métodos para su uso

Also Published As

Publication number Publication date
EP2596790A1 (en) 2013-05-29
CO6290687A2 (es) 2011-06-20
KR20100120709A (ko) 2010-11-16
WO2009109576A1 (en) 2009-09-11
BRPI0909102A2 (pt) 2019-01-15
EP2596790B1 (en) 2015-12-09
CN104098559A (zh) 2014-10-15
AU2009221134B2 (en) 2012-02-23
EP2262802A1 (en) 2010-12-22
JP5412448B2 (ja) 2014-02-12
CN102015701A (zh) 2011-04-13
JP2011513363A (ja) 2011-04-28
PE20091577A1 (es) 2009-11-05
ZA201006128B (en) 2011-10-26
MX2010009739A (es) 2010-09-28
EA201001412A1 (ru) 2011-06-30
EP2262802B1 (en) 2013-10-23
CL2009000483A1 (es) 2010-02-19
CA2717388A1 (en) 2009-09-11
AU2009221134A1 (en) 2009-09-11
MA32135B1 (fr) 2011-03-01
ES2562306T3 (es) 2016-03-03
TW200942536A (en) 2009-10-16
ES2443496T3 (es) 2014-02-19
AR070531A1 (es) 2010-04-14
CN102015701B (zh) 2014-07-23
UY31679A1 (es) 2009-09-30
IL207865A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
UY31679A1 (es) Inhibidores de cinasa pim y metodos para su uso
CR20120130A (es) Compuestos de benzoxepina inhibidores de la pi3k y métodos de uso
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
MX2013006858A (es) Compuesto triciclicos inhibidores de la pi3k y metodos de uso.
ECSP11011198A (es) Derivados de sulfonamida
MA32272B1 (fr) Inhibiteurs de raf de pyrazole [3,4-b]pyridine
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
ECSP088630A (es) Derivados de pirimidina utilizados como inhibidores de cinasa pi-3
CR20140544A (es) Compuestos para inhibir la progresión mitotica
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
UY31906A (es) Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias.
UY33075A (es) Derivados de ciclohexano y usos de los mismos
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
EA201101435A1 (ru) Имидазотиадиазолы для применения в качестве ингибиторов киназ
SV2009003389A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
CU20110113A7 (es) Lactamas como inhibidores beta secretasa
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
CO6361855A2 (es) Derivados de 7-hidroxi-benzoimidazol-4-il-,etanona e inhibidores de cinasa que enlaza pdz que contienen los mismos
CL2023002486A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
CR11860A (es) Derivados de dibenzotiazepina y sus usos - 424
ECSP109885A (es) Compuestos de cinolina para su uso en el tratamiento de la esquizofrenia
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
TN2010000402A1 (en) Pim kinase inhibitors and methods of their use